Compare VYGR & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | PROF |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 270.7M |
| IPO Year | 2015 | 2017 |
| Metric | VYGR | PROF |
|---|---|---|
| Price | $3.76 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $21.00 | $12.00 |
| AVG Volume (30 Days) | ★ 837.1K | 239.4K |
| Earning Date | 03-09-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | $10,135,000.00 | ★ $16,098,000.00 |
| Revenue This Year | $54.19 | $115.41 |
| Revenue Next Year | $20.22 | $60.63 |
| P/E Ratio | ★ N/A | $3.87 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.65 | $3.90 |
| 52 Week High | $5.55 | $8.95 |
| Indicator | VYGR | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 36.04 |
| Support Level | $3.60 | $5.45 |
| Resistance Level | $4.43 | $5.94 |
| Average True Range (ATR) | 0.33 | 0.56 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 4.37 | 19.48 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.